This study describes a quencher-free fluorescent aptasensor for ochratoxin A (OTA) detection using the specific quenching ability of guanine for fluorescein (FAM) molecules based on photo-induced electron transfer (PIET). In this strategy, OTA is detected by monitoring the fluorescence change induced by the conformational change of the aptamer after target binding. A new shorter OTA aptamer compromising three guanine bases at the 5′ end was used in this study. This new aptamer, named G3-OTAapt1-FAM (F1), was labeled with FAM on the 3′ end as a fluorophore. In order to increase the binding affinity of the aptamer and OTA, G3-OTAapt2-FAM (F2) was designed; this added a pair of complementary bases at the end compared with F1. To prevent the strong self-quenching of F2, a complementary chain, A13, was added. Although the F1 aptasensor was simpler to implement, the sensitivity of the F2 aptasensor with A13 was better than that of F1. The proposed F1 and F2 sensors can detect OTA with a concentration as low as 0.69 nmol/L and 0.36 nmol/L, respectively.
Microbial fatty acids are synthesized by Type II fatty acid synthase and could be tailored by acyl-ACP thioesterase. With the prospects of medium-chain fatty-acid-derivative biofuels, the selectivity of thioesterase has been studied to control the fatty acid product chain length. Here, we report an alternative approach by manipulating the acyl carrier protein portion of acyl-ACP to switch the chain length propensity of the thioesterase. It was demonstrated that ChFatB2 from Cuphea hookeriana preferred C10-ACP to C8-ACP with ACP from E. coli, while converting preference to C8-ACP with ACP from Cuphea lanceolate. Circular dichroism (CD) results indicated that the C8-EcACP encountered a 34.4% α-helix increment compared to C10-EcACP, which resulted in an approximate binding affinity decrease in ChFatB2 compared to C10-EcACP. Similarly, the C10-ClACP2 suffered a 45% decrease in helix content compared to C8–ClACP2, and the conformational changes resulted in an 18% binding affinity decline with ChFatB2 compared with C10-ClACP2. In brief, the study demonstrates that the ACP portion of acyl-ACP contributes to the selectivity of acyl-ACP thioesterase, and the conformational changes of EcACP and ClACP2 switch the chain length preference of ChFatB2 between C8 and C10. The result provides fundamentals for the directed synthesis of medium-chain fatty acids based on regulating the conformational changes of ACPs.
13 August 2025 in Human Vaccines & Immunotherapeutics
The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of Bordetella pertussis, highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract. Incorporating novel adjuvants represents a promising avenue for the future development of pertussis vaccines. Nevertheless, there remains a significant gap in understanding the application of novel adjuvants. In this article, we summarize the currently approved pertussis vaccines, focusing on the types of antigens and adjuvants used, and discuss the mechanisms of novel adjuvants. This provides valuable insights into the roles of adjuvants in pertussis vaccines, laying a foundation for designing next-generation pertussis vaccines with improved adjuvant systems.
Aluminum hydroxyphosphate (AAHP) and aluminum oxyhydroxide (AlOOH) are widely used adjuvants in human vaccines. However, vaccines formulated with aluminum-based adjuvants often exist as suspensions that can experience phase separation, spontaneous aggregation, layering, and settling, potentially compromising their immunogenic efficacy. Despite their widespread use, research into the suspension stability of aluminum-based adjuvants remains limited. In this study, we synthesized a series of aluminum hydroxyphosphate and AlOOH nanoparticles and systematically evaluated their suspension stabilities under various conditions. Our findings reveal that for aluminum hydroxyphosphate, particle size and ζ potential are the primary determinants of suspension stability, aligning with DLVO theory and Stokes’ law. For AlOOH, the suspension stability is governed by a combination of factors, including particle size, ζ potential, surface free energy (SFE) and hydrophobicity. Notably, the commercial adjuvant Alhydrogel® exhibited low suspension stability compared to our synthesized AlOOH nanoparticles, a result attributed to its high SFE. Furthermore, under specific formulation conditions, aluminum-based adjuvants with enhanced suspension stability improved the suspension stability of their corresponding adjuvant-antigen complexes. This study provides a foundation for optimizing the suspension stability of aluminum-based adjuvants and offers valuable insights for their rational design and transportation in vaccine development.
9 October 2023 in Journal of Pharmaceutical Sciences